Skip to main content
Top
Published in: BMC Pregnancy and Childbirth 1/2019

Open Access 01-12-2019 | Antidepressant Drugs | Research article

Treatment resistant depression in women with peripartum depression

Authors: M. Soledad Cepeda, David M. Kern, Susan Nicholson

Published in: BMC Pregnancy and Childbirth | Issue 1/2019

Login to get access

Abstract

Background

Peripartum depression is a leading cause of disease burden for women and yet there is little evidence as to how often peripartum depression does not respond to treatment and becomes treatment resistant depression. We sought to determine the incidence of treatment resistant depression (TRD) in women with peripartum depression.

Methods

Population based retrospective cohort study using a large US claims database. Peripartum depression was defined as having a depression diagnosis during pregnancy or up to 6 months after the end of pregnancy. We included women with prevalent or incident depression. The outcome was the development of TRD within 1 year after the diagnosis of peripartum depression. TRD was defined as having 3 distinct antidepressants or 1 antidepressant and 1 antipsychotic in 1 year.
Women with peripartum depression may not be exposed to pharmacological treatments early in pregnancy, therefore we created two groups: 1. women with peripartum depression, and 2. women with peripartum depression diagnosed 3 months before a live birth delivery or within 6 months after that delivery.

Results

There were 3,207,684 pregnant women, of whom 2.5% had peripartum depression. Of these women half had incident depression during pregnancy. Five percent of women with peripartum depression developed TRD within 1 year of the depression diagnosis. The risk of developing TRD was 50% higher in women with prevalent depression than in women with incident peripartum depression (P < 0.0001). Results were similar in women with peripartum depression diagnosed later in their pregnancy.
Women who went on to develop TRD had more substance use disorders, anxiety, insomnia and painful conditions.

Conclusions

TRD occurs in approximately 5% of women with peripartum depression. The risk of TRD is higher in pregnant women with a history of depression. Women who went on to develop TRD had more psychiatric comorbidities and painful conditions than women who did not.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hahn-Holbrook J, Cornwell-Hinrichs T, Anaya I. Economic and Health Predictors of National Postpartum Depression Prevalence: A Systematic Review, Meta-analysis, and Meta-Regression of 291 Studies from 56 Countries. Front Psych. 2018;8(248). DOI: https://doi.org/10.3389/fpsyt.2017.00248. Hahn-Holbrook J, Cornwell-Hinrichs T, Anaya I. Economic and Health Predictors of National Postpartum Depression Prevalence: A Systematic Review, Meta-analysis, and Meta-Regression of 291 Studies from 56 Countries. Front Psych. 2018;8(248). DOI: https://​doi.​org/​10.​3389/​fpsyt.​2017.​00248.
2.
go back to reference Eastwood J, Ogbo FA, Hendry A, Noble J. Page A, for the Early Years Research G. The Impact of Antenatal Depression on Perinatal Outcomes in Australian Women. PLoS One. 2017;12(1):e0169907.CrossRef Eastwood J, Ogbo FA, Hendry A, Noble J. Page A, for the Early Years Research G. The Impact of Antenatal Depression on Perinatal Outcomes in Australian Women. PLoS One. 2017;12(1):e0169907.CrossRef
3.
go back to reference Halter MJ, Rolin-Kenny D, Grund F. DSM-5: historical perspectives. J Psychosoc Nurs Ment Health Serv. 2013;51(4):22–9.CrossRef Halter MJ, Rolin-Kenny D, Grund F. DSM-5: historical perspectives. J Psychosoc Nurs Ment Health Serv. 2013;51(4):22–9.CrossRef
4.
go back to reference American Psychiatric Association. Unspecified Depressive Disorder. In: Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington: American Psychiatric Association; 2013.CrossRef American Psychiatric Association. Unspecified Depressive Disorder. In: Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington: American Psychiatric Association; 2013.CrossRef
5.
go back to reference Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. Br J Psychiatry. 1987;150:662–73.CrossRef Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. Br J Psychiatry. 1987;150:662–73.CrossRef
6.
go back to reference O’Hara MW, McCabe JE. Postpartum depression: current status and future directions. Annu Rev Clin Psychol. 2013;9:379–407.CrossRef O’Hara MW, McCabe JE. Postpartum depression: current status and future directions. Annu Rev Clin Psychol. 2013;9:379–407.CrossRef
7.
go back to reference Robertson-Blackmore E, Putnam FW, Rubinow DR, Matthieu M, Hunn JE, Putnam KT, et al. Antecedent trauma exposure and risk of depression in the perinatal period. J Clin Psychiatry. 2013;74(10):e942–8.CrossRef Robertson-Blackmore E, Putnam FW, Rubinow DR, Matthieu M, Hunn JE, Putnam KT, et al. Antecedent trauma exposure and risk of depression in the perinatal period. J Clin Psychiatry. 2013;74(10):e942–8.CrossRef
8.
go back to reference Gavin NI, Gaynes BN, Lohr KN, Meltzer-Brody S, Gartlehner G, Swinson T. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol. 2005;106(5 Pt 1):1071–83.CrossRef Gavin NI, Gaynes BN, Lohr KN, Meltzer-Brody S, Gartlehner G, Swinson T. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol. 2005;106(5 Pt 1):1071–83.CrossRef
9.
go back to reference Centers for Disease Control and Prevention. Decline in Postpartum Depression. Jama. 2017;317(12):1207. Centers for Disease Control and Prevention. Decline in Postpartum Depression. Jama. 2017;317(12):1207.
10.
go back to reference Ko JY, Rockhill KM, Tong VT, Morrow B, Farr SL. Trends in postpartum depressive symptoms - 27 states, 2004, 2008, and 2012. MMWR Morb Mortal Wkly Rep. 2017;66(6):153–8.CrossRef Ko JY, Rockhill KM, Tong VT, Morrow B, Farr SL. Trends in postpartum depressive symptoms - 27 states, 2004, 2008, and 2012. MMWR Morb Mortal Wkly Rep. 2017;66(6):153–8.CrossRef
11.
go back to reference Russell JM, Hawkins K, Ozminkowski RJ, Orsini L, Crown WH, Kennedy S, et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry. 2004;65(3):341–7.CrossRef Russell JM, Hawkins K, Ozminkowski RJ, Orsini L, Crown WH, Kennedy S, et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry. 2004;65(3):341–7.CrossRef
12.
go back to reference Berlim MT, Turecki G. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol. 2007;17(11):696–707.CrossRef Berlim MT, Turecki G. What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol. 2007;17(11):696–707.CrossRef
13.
go back to reference Gaynes BN, Asher G, Gartlehner G, Hoffman V, Green J, Boland E, et al. AHRQ Technology Assessments. In: Definition of Treatment-Resistant Depression in the Medicare Population. Rockville: Agency for Healthcare Research and Quality (US); 2018. Gaynes BN, Asher G, Gartlehner G, Hoffman V, Green J, Boland E, et al. AHRQ Technology Assessments. In: Definition of Treatment-Resistant Depression in the Medicare Population. Rockville: Agency for Healthcare Research and Quality (US); 2018.
14.
go back to reference Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–17.CrossRef Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–17.CrossRef
15.
go back to reference Conway CR, George MS, Sackeim HA. Toward an evidence-based, operational definition of treatment-resistant depression: when enough is enough. JAMA Psychiat. 2017;74(1):9–10.CrossRef Conway CR, George MS, Sackeim HA. Toward an evidence-based, operational definition of treatment-resistant depression: when enough is enough. JAMA Psychiat. 2017;74(1):9–10.CrossRef
16.
go back to reference Solberg LI, Engebretson KI, Sperl-Hillen JM, Hroscikoski MC, O'Connor PJ. Are claims data accurate enough to identify patients for performance measures or quality improvement? The case of diabetes, heart disease, and depression. Am J Med Qual. 2006;21(4):238–45.CrossRef Solberg LI, Engebretson KI, Sperl-Hillen JM, Hroscikoski MC, O'Connor PJ. Are claims data accurate enough to identify patients for performance measures or quality improvement? The case of diabetes, heart disease, and depression. Am J Med Qual. 2006;21(4):238–45.CrossRef
17.
go back to reference Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. Jama. 2006;295(5):499–507.CrossRef Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. Jama. 2006;295(5):499–507.CrossRef
18.
go back to reference Payne JL, Meltzer-Brody S. Antidepressant use during pregnancy: current controversies and treatment strategies. Clin Obstet Gynecol. 2009;52(3):469–82.CrossRef Payne JL, Meltzer-Brody S. Antidepressant use during pregnancy: current controversies and treatment strategies. Clin Obstet Gynecol. 2009;52(3):469–82.CrossRef
19.
go back to reference Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, et al. Efficacy and safety of intranasal Esketamine adjunctive to Oral antidepressant therapy in treatment-resistant depression: a randomized clinical TrialEfficacy and safety of intranasal Esketamine in DepressionEfficacy and safety of intranasal Esketamine in depression. JAMA Psychiat. 2018;75(2):139–48.CrossRef Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, et al. Efficacy and safety of intranasal Esketamine adjunctive to Oral antidepressant therapy in treatment-resistant depression: a randomized clinical TrialEfficacy and safety of intranasal Esketamine in DepressionEfficacy and safety of intranasal Esketamine in depression. JAMA Psychiat. 2018;75(2):139–48.CrossRef
20.
go back to reference Cepeda MS, Reps J, Ryan P. Finding factors that predict treatment-resistant depression: results of a cohort study. Depress Anxiety. 2018;35(7):668–73.CrossRef Cepeda MS, Reps J, Ryan P. Finding factors that predict treatment-resistant depression: results of a cohort study. Depress Anxiety. 2018;35(7):668–73.CrossRef
21.
go back to reference Matcho A, Ryan P, Fife D, Gifkins D, Knoll C, Friedman A. Inferring pregnancy episodes and outcomes within a network of observational databases. PLoS One. 2018;13(2):e0192033.CrossRef Matcho A, Ryan P, Fife D, Gifkins D, Knoll C, Friedman A. Inferring pregnancy episodes and outcomes within a network of observational databases. PLoS One. 2018;13(2):e0192033.CrossRef
22.
go back to reference Reich C, Ryan PB, Stang PE, Rocca M. Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform. 2012;45(4):689–96.CrossRef Reich C, Ryan PB, Stang PE, Rocca M. Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases. J Biomed Inform. 2012;45(4):689–96.CrossRef
23.
go back to reference Cepeda MS, Reps J, Fife D, Blacketer C, Stang P, Ryan P. Finding treatment-resistant depression in real-world data: how a data-driven approach compares with expert-based heuristics. Depress Anxiety. 2018;35(3):220–8.CrossRef Cepeda MS, Reps J, Fife D, Blacketer C, Stang P, Ryan P. Finding treatment-resistant depression in real-world data: how a data-driven approach compares with expert-based heuristics. Depress Anxiety. 2018;35(3):220–8.CrossRef
24.
go back to reference Fife D, Reps J, Cepeda MS, Stang P, Blacketer M, Singh J. Treatment resistant depression incidence estimates from studies of health insurance databases depend strongly on the details of the operating definition. Heliyon. 2018;4(7):e00707.CrossRef Fife D, Reps J, Cepeda MS, Stang P, Blacketer M, Singh J. Treatment resistant depression incidence estimates from studies of health insurance databases depend strongly on the details of the operating definition. Heliyon. 2018;4(7):e00707.CrossRef
25.
go back to reference Cox EQ, Sowa NA, Meltzer-Brody SE, Gaynes BN. The perinatal depression treatment Cascade: baby steps toward improving outcomes. J Clin Psychiatry. 2016;77(9):1189–200.CrossRef Cox EQ, Sowa NA, Meltzer-Brody SE, Gaynes BN. The perinatal depression treatment Cascade: baby steps toward improving outcomes. J Clin Psychiatry. 2016;77(9):1189–200.CrossRef
26.
go back to reference Flynn HA, Blow FC, Marcus SM. Rates and predictors of depression treatment among pregnant women in hospital-affiliated obstetrics practices. Gen Hosp Psychiatry. 2006;28(4):289–95.CrossRef Flynn HA, Blow FC, Marcus SM. Rates and predictors of depression treatment among pregnant women in hospital-affiliated obstetrics practices. Gen Hosp Psychiatry. 2006;28(4):289–95.CrossRef
27.
go back to reference Molyneaux E, Trevillion K, Howard LM. Antidepressant treatment for postnatal depression. Jama. 2015;313(19):1965–6.CrossRef Molyneaux E, Trevillion K, Howard LM. Antidepressant treatment for postnatal depression. Jama. 2015;313(19):1965–6.CrossRef
28.
go back to reference Drozdowicz-Jastrzebska E, Skalski M, Gdanska P, Mach A, Januszko P, Nowak RJ, et al. Insomnia, postpartum depression and estradiol in women after delivery. Metab Brain Dis. 2017;32(6):1913–8.CrossRef Drozdowicz-Jastrzebska E, Skalski M, Gdanska P, Mach A, Januszko P, Nowak RJ, et al. Insomnia, postpartum depression and estradiol in women after delivery. Metab Brain Dis. 2017;32(6):1913–8.CrossRef
29.
go back to reference Suri R, Stowe ZN, Cohen LS, Newport DJ, Burt VK, Aquino-Elias AR, et al. Prospective longitudinal study of predictors of postpartum-onset depression in women with a history of major depressive disorder. J Clin Psychiatry. 2017;78(8):1110–6.CrossRef Suri R, Stowe ZN, Cohen LS, Newport DJ, Burt VK, Aquino-Elias AR, et al. Prospective longitudinal study of predictors of postpartum-onset depression in women with a history of major depressive disorder. J Clin Psychiatry. 2017;78(8):1110–6.CrossRef
30.
go back to reference Putnam KT, Wilcox M, Robertson-Blackmore E, Sharkey K, Bergink V, Munk-Olsen T, et al. Clinical phenotypes of perinatal depression and time of symptom onset: analysis of data from an international consortium. Lancet Psychiatry. 2017;4(6):477–85.CrossRef Putnam KT, Wilcox M, Robertson-Blackmore E, Sharkey K, Bergink V, Munk-Olsen T, et al. Clinical phenotypes of perinatal depression and time of symptom onset: analysis of data from an international consortium. Lancet Psychiatry. 2017;4(6):477–85.CrossRef
31.
go back to reference Ionescu DF, Niciu MJ, Richards EM, Zarate CA Jr. Pharmacologic treatment of dimensional anxious depression: a review. Prim Care Companion CNS Disord. 2014;16(3). Ionescu DF, Niciu MJ, Richards EM, Zarate CA Jr. Pharmacologic treatment of dimensional anxious depression: a review. Prim Care Companion CNS Disord. 2014;16(3).
32.
go back to reference Hui Poon S, Sim K, Baldessarini RJ. Pharmacological approaches for treatment-resistant bipolar disorder. Curr Neuropharmacol. 2015;13(5):592–604.CrossRef Hui Poon S, Sim K, Baldessarini RJ. Pharmacological approaches for treatment-resistant bipolar disorder. Curr Neuropharmacol. 2015;13(5):592–604.CrossRef
33.
go back to reference Rybakowski JK. Bipolar mood disorder and treatment-resistant depression. Ann General Psychiatry. 2010;9(Suppl 1):S14-S.CrossRef Rybakowski JK. Bipolar mood disorder and treatment-resistant depression. Ann General Psychiatry. 2010;9(Suppl 1):S14-S.CrossRef
34.
go back to reference Robertson E, Grace S, Wallington T, Stewart DE. Antenatal risk factors for postpartum depression: a synthesis of recent literature. Gen Hosp Psychiatry. 2004;26(4):289–95.CrossRef Robertson E, Grace S, Wallington T, Stewart DE. Antenatal risk factors for postpartum depression: a synthesis of recent literature. Gen Hosp Psychiatry. 2004;26(4):289–95.CrossRef
35.
go back to reference Burke L. The impact of maternal depression on familial relationships. Int Rev Psychiatry. 2003;15(3):243–255CrossRef Burke L. The impact of maternal depression on familial relationships. Int Rev Psychiatry. 2003;15(3):243–255CrossRef
36.
go back to reference Cogill SR, Caplan HL, Alexandra H, Robson KM, Kumar R. Impact of maternal postnatal depression on cognitive development of young children. Br Med J (Clin Res Ed). 1986;292(6529):1165–7.CrossRef Cogill SR, Caplan HL, Alexandra H, Robson KM, Kumar R. Impact of maternal postnatal depression on cognitive development of young children. Br Med J (Clin Res Ed). 1986;292(6529):1165–7.CrossRef
Metadata
Title
Treatment resistant depression in women with peripartum depression
Authors
M. Soledad Cepeda
David M. Kern
Susan Nicholson
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Pregnancy and Childbirth / Issue 1/2019
Electronic ISSN: 1471-2393
DOI
https://doi.org/10.1186/s12884-019-2462-9

Other articles of this Issue 1/2019

BMC Pregnancy and Childbirth 1/2019 Go to the issue